Kadmon Holdings announced that tesevatinib has been granted Orphan Drug designation by the Food and Drug Administration (FDA) to treat non-small cell lung cancer (NSCLC) with epithelial growth factor receptor (EGFR)-activating mutations.

Tesevatinib, an oral reversible and potent tyrosine kinase inhibitor, is currently being assessed in Phase 2 clinical trials for the treatment of EGFR-mutation-positive NSCLC that has metastasized to the brain and/or the leptomeninges and also for the treatment of glioblastoma. 

Related Articles

In March 2016, tesevatinib was designated Orphan Drug status for the treatment of autosomal recessive polycystic kidney disease (ARPKD). 

For more information visit Kadmon.com